ViaNautis Bio welcomed SCI Ventures as new investor, expanding CNS portfolio into spinal cord injury ViaNautis Bio, the biotech developing polyNaut® for precise, non‑viral delivery of genetic medicines, announced that SCI Ventures, a specialist venture fund backed by leading clinical centres and research foundations worldwide focused on advancing treatments and cures for paralysis, has joined the […]
Study shows TT-P34 is safe and well tolerated in healthy volunteers and patients with early-stage Parkinson’s disease (PD), with pharmacokinetics confirming robust CNS exposure Early biomarker signals are consistent with pathway modulation in the brain Teitur is planning to start a Phase II clinical trial of TT-P34 in PD in 2027 Aarhus, Denmark, September 10, […]
Financing co-led by Sunstone Life Science Ventures and Sound Bioventures with participation from Industrifonden, Innovestor’s Life Science Fund and P53 Invest Discovery of a novel mechanism with the potential to prevent the death of neurons in neurodegenerative diseases First-in-Class, lead drug candidate advances into clinical development in a Phase 1b study Aarhus, Denmark March 14th, […]
